Page 6 - Managed Care News Today

“The American people deserve to know that the insurance companies receiving more than $700B annually in taxpayer funds are working to ensure you receive effective, high-quality care....

Sharecare, Inc. misses on earnings expectations. Reported EPS is $-0.03 EPS, expectations were $-0.0195.

Part 1 of a 3-part, monthly feature series on the history, evolution, and current state of LGBTQ+ health care is focused on the unique needs and journey of transgender patients in the US health system, as well as the policies and social influences that have shaped their access to care.

Response rates are important when choosing between therapies to treat multiple myeloma (MM), but improvement overall survival (OS) is the ideal, said Chakra Chaulagain MD, FACP, hematologist/oncologist, Maroone Cancer Center of Cleveland Clinic Florida.

Ryan Haumschild, PharmD, MS, MBA, leads a discussion on factors that influence coverage of non-oncology gene therapies, exploring the balance between long-term cost savings and high initial prices, patient selection, and the durability of effect for these therapies.

While there is, rightfully, a lot of optimism around the latest treatments for newly diagnosed multiple myeloma, not everyone is gaining the same benefit, said Kenneth Shain, MD, PhD, of H. Lee Moffitt Cancer Center.

The agency has authorized accelerated payments to help providers facing cash flow problems after a ransomware attack last month delayed payer reimbursements.

Experts discuss the landscape of treatment options for Duchenne muscular dystrophy, examine the benefits and risks of gene therapy and conventional steroid treatments, and emphasize the need for early intervention and comprehensive care.

Experts at the American Academy of Dermatology Annual Meeting shared results of research into various topical and systemic therapies for atopic dermatitis (AD) and hidradenitis suppurativa during a late-breaking abstract session.

Ramirez Asset Management Inc. bought a new stake in Centene Co. (NYSE:CNC – Free Report) in the third quarter, HoldingsChannel reports. The fund bought 1,499 shares of the company’s stock, valued at approximately $103,000. Other hedge funds have also added to or reduced their stakes in the company. Operose Advisors LLC acquired a new stake […]